Leal Therapeutics’ $30M Series A Advances CNS Pipeline

Leal Therapeutics announced a $30M Series A on August 27, 2025, led by SV Health Investors’ Dementia Discovery Fund. Existing investors OrbiMed, Newpath Partners, Chugai Venture Fund, Euclidean Capital, Alexandria Venture Investments, and PhiFund also participated. The financing was designated to advance Leal’s neuro-metabolic pipeline, particularly LTX-001 for schizophrenia and LTX-002 for amyotrophic lateral sclerosis, or ALS.

The round matters because Leal is applying metabolic biology to central nervous system disorders that have resisted decades of drug development. The company is not merely funding another discovery-stage theory: by June 2026, LTX-001 had moved through part of a Phase 1 study and LTX-002 had entered a Phase 1/2 clinical trial. That progression turns the financing story into a measurable clinical-development story.

What Happened

The $30M Series A gave Leal capital to move LTX-001 through a clinical trial in patients with schizophrenia and to produce initial clinical data for LTX-002 in ALS. Christian Jung, a partner at SV Health Investors and co-leader of the Dementia Discovery Fund, joined Leal’s board in connection with the financing. The company’s official announcement describes the transaction as a $30M Series A, but it does not call it a second close.

The Series A followed a $45M financing announced in October 2024, which itself followed a previously disclosed $39M financing. Across those three publicly disclosed financings, Leal has announced $114M in capital. The company has not publicly disclosed a valuation in the primary sources reviewed for this article.

Why This Matters

Leal’s thesis is that metabolic imbalances in the brain can provide tractable targets for neuropsychiatric and neurodegenerative disease. LTX-001 is a brain-penetrant oral small molecule that inhibits the mitochondrial enzyme glutaminase, or GLS1, to address excessive glutamate. Leal is developing the program for schizophrenia, where the company has reported early evidence of safety, tolerability, and central nervous system target engagement from Phase 1 testing.

LTX-002 takes a different route. The intrathecally delivered antisense oligonucleotide targets SPTLC1, a core subunit of serine palmitoyltransferase, with the goal of reducing excessive ceramides and sphingolipids implicated in motor-neuron toxicity. Leal is studying the program in both genetic and sporadic ALS, which broadens the potential relevance beyond mutation-defined patient groups if the mechanism proves safe and effective.

The business lesson is not that a compelling biological thesis removes clinical risk. It is that financing becomes more useful when it is tied to falsifiable milestones. Leal’s investors funded named programs, defined targets, and specific trial objectives. That makes progress easier to assess than a broad promise to transform neuroscience.

Clinical Progress Since the Series A

In April 2026, Leal reported that LTX-001 had completed the single-ascending-dose portion of its Phase 1 trial with what the company characterized as a favorable safety and tolerability profile and dose-dependent CNS target engagement. The company also said the multiple-ascending-dose portion was underway and a Phase 1b/2a study in schizophrenia was expected to begin in mid-2026. Those statements are company-reported clinical updates, not peer-reviewed efficacy findings.

The ALS program moved into human testing in 2026. On June 23, Leal said it had dosed the first participant in NeurALS, a Phase 1/2 study of LTX-002. The ClinicalTrials.gov record lists the trial as recruiting, with an estimated enrollment of 56 adults and endpoints covering safety, tolerability, pharmacokinetics, biomarkers, and clinical measures.

Leadership and Investor Logic

Leal was founded in 2021 and is headquartered in Worcester, Massachusetts. Founder and CEO Asa Abeliovich previously founded Prevail Therapeutics, which Eli Lilly acquired in 2021, and co-founded Alector. CTO Eduardo Paredes brings experience in oligonucleotide development, manufacturing, process development, and regulatory filings, while the current leadership team also includes CMO Johannes Tauscher and CBO Raymond Jordt.

That operating history matters in a field where the gap between target discovery and clinical execution can swallow years and capital. It also helps explain the investor mix: the Series A combined a specialist neurodegeneration lead investor with returning life-sciences funds that had already financed Leal. DDF’s board participation added domain oversight at the point when the company’s programs were moving deeper into human studies.

What This Signals

The financing reflects a broader shift in neuroscience company-building toward mechanisms supported by human genetics, biomarkers, and measurable target engagement. That approach does not guarantee therapeutic success, but it can tighten the chain of evidence between biological hypothesis, dose selection, and clinical interpretation. For investors and operators, the advantage is clearer decision-making before the most expensive stages of development.

Leal’s next meaningful proof points are clinical, not financial. LTX-001 must show whether early target-engagement findings can translate into patient benefit in schizophrenia, while LTX-002 must establish safety and biological activity in ALS. The $30M Series A bought the company time and capability to ask those questions in people; the answers will determine whether neuro-metabolic therapeutics become a durable CNS strategy or another promising idea that biology refuses to sign.